Profile: Transition Therapeutics Inc (TTHI.OQ)
25 Aug 2014
Transition Therapeutics Inc. (Transition), incorporated on July 6, 1998, is a product-focused biopharmaceutical company developing novel therapeutics for disease indications with large markets. The Company’s s technologies in development are ELND005 (AZD-103) for the treatment of Alzheimer’s disease and bipolar disorder; TT-401/402 for the treatment of diabetes ,and TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, neuropathic pain, Alzheimer’s disease, traumatic brain injury and intracerebral haemorrhage. The Company has one wholly owned material subsidiary, Waratah Pharmaceuticals Inc. (Waratah), which is engaged in the development and commercialization of its ELND005 (AZD-103); the type II diabetes drug candidate TT-401; and TT-301 and TT-302.
ELND005 (AZD-103) Technology
The Company is engaged in developing disease-modifying small molecule therapeutics that act by preventing the formation of and breaking down amyloid beta peptide aggregates. The accumulation of amyloid beta has been connected to several diseases including Alzheimer’s disease, AA Amyloidosis and others. The Alzheimer’s disease product, ELND005 (AZD-103), is part of of disease-modifying drugs that have the potential to both reduce disease progression and improve symptoms, such as diminished cognitive function. ELND005 (AZD-103) breaks down neuro-toxic fibrils, allowing amyloid peptides to clear the brain rather than form amyloid plaques, a hallmark pathology of Alzheimer’s disease. The Company and its licensing partner, Elan, has performed multiple Phase I studies evaluating the safety, tolerability and pharmacokinetic profile of ELND005 (AZD-103) in healthy volunteers. ELND005 (AZD-103) was also shown to be orally bioavailable, to cross the blood-brain barrier. Biologically, ELND005 treatment was also associated with reductions in myo-inositol levels in the brain, a mechanism of action common to other neuropsychiatric drugs, including lithium and valproic acid.
TT-401 / TT-402
The Company’s TT-401 provides glycemic control and other effects, including weight loss. In June, 2012, Transition announced the results of the Phase I clinical study of type II diabetes drug candidate. TT-401 exhibited the pharmacological effect on glucose and pharmacodynamic biomarkers at doses that were safe and tolerable.
TT-301 / TT-302
The Company is engaged in developing a class of small molecule compounds that are designed to cross the blood brain barrier and have been shown to have an inhibitory effect on pro-inflammatory cytokines. The Company’s lead drug candidates in development are TT-301 and TT-302. These drug candidates are derived from a diligent drug design program engineered to produce compounds optimized to target inhibiting pro-inflammatory cytokines in the brain and periphery. Each compound is designed to cross the blood-brain-barrier and each has the flexibility to be administered by injection or orally. The Company has also performed additional preclinical studies demonstrating the potential therapeutic application of TT-301 and TT-302 in the treatment of neuropathic pain.
Transition Therapeutics Inc
SUITE 220, 101 COLLEGE STREET
TORONTO ON M5G 1L7